GlassScriptPhysician profile
Raymond E De La Rosa
NPI 1083667984
$21,953.38
in general payments reported to CMS, 2019-2025
44 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $958 · 2021: $649 · 2022: $675 · 2023: $2,143 · 2024: $1,275 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,397 · Consulting Fee: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,396.81 |
| Consulting Fee | $870.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15,966.40 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $1,139.25 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $741.60 | 2019-2025 | Tepezza, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $588.92 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $511.75 | 2019-2025 | Farxiga, Saphnelo, Airsupra |
| Radius Health, INC. | $354.45 | 2019-2024 | Tymlos |
| Esperion Therapeutics, INC. | $253.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $218.48 | 2022-2025 | |
| Lilly USA, LLC | $216.43 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Sanofi-Aventis U.S. LLC | $172.86 | 2024 | |
| Dexcom, INC. | $161.46 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $157.39 | 2025 | |
| Abbvie INC. | $144.95 | 2020-2024 | Vraylar, Qulipta |
| Ucb, INC. | $120.44 | 2024-2025 | Bimzelx |
| Corcept Therapeutics | $119.92 | 2020-2025 | Korlym |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond De La Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.